Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study

BACKGROUND: In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1–4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients with advanced CKD. This analysis further explores kidn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruilope, Luis M, Pitt, Bertram, Anker, Stefan D, Rossing, Peter, Kovesdy, Csaba P, Pecoits-Filho, Roberto, Pergola, Pablo, Joseph, Amer, Lage, Andrea, Mentenich, Nicole, Scheerer, Markus F, Bakris, George L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923706/
https://www.ncbi.nlm.nih.gov/pubmed/35451488
http://dx.doi.org/10.1093/ndt/gfac157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923706/
https://www.ncbi.nlm.nih.gov/pubmed/35451488
http://dx.doi.org/10.1093/ndt/gfac157

Ejemplares similares